
A Smarter Urine Test for Bladder Cancer
As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are


As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are

Chugai Pharmaceutical Co., Ltd. announced that Roche has made the strategic decision to discontinue clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin antibody, for

As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults

Most of us have heard of the fight-or-flight stress response. It becomes activated when we believe there is a chance we can outfight or outrun

Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology’s most challenging cancers. As reported

I have battled several autoimmune and neurological conditions that are triggered by food and other factors for over 50 years. It took most of my

The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model

As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal

Editor’s Note: Patient Worthy is pleased to share the final part in a series of excerpts by Dana Langston. Chapter 36: Holding the Line Knowing

For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch

As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with

Editor’s Note: Patient Worthy is pleased to share part 4 of 5 in a series of excerpts written by Dana Langston. Part 7: Legacy &

When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants,

As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the

Editor’s Note: Patient Worthy is proud to bring you part 3 of 5 in a series of excerpts written by Dana Langston. Part 3: The

Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases

As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people

Editor’s Note: This is the second part in a series of excerpts written by Dana Langston. Chapter 4: The Internal Shift We are living in
Not every health issue is visible- and that's why awareness matters.
Oral cancer can start quickly, with small changes like a sore that won't heal, unusual lumps, or persistent pain. These signs are easy to overlook, but catching them early can make a life-saving difference.
This Oral Cancer Awareness Month, take a moment to check in with your health. Stay informed, keep up with dental visits, and don’t ignore what your body is trying to tell you. Awareness isn't just knowledge- it's prevention, action, and care. #OralCancerAwareness #OralHealth #PatientWorthy
... See MoreSee Less

Neurofibromatosis Network- CAMP can be an amazing experience for rare disease kids ... See MoreSee Less


United Leukodystrophy FoundationIn recognition of #NationalPublicHealthWeek, we’re honored to host the ULF Annual Scientific Symposium and Family Conference, taking place June 25–27, 2026.
This special gathering offers a meaningful opportunity to learn, collaborate, and connect within the leukodystrophy community. Whether you are a family impacted by leukodystrophy, a medical professional, or a researcher, the Symposium and Conference provide a welcoming space for education, shared insight, and empowerment. Register today: ulf.org/scientific-symposium-family-conference/ #ULFConference #Leukodystrophy
... See MoreSee Less

© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.